Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
June 5, 2023

NMPA grants BTD to Innovent’s olverembatinib to treat SDH-deficient GIST

The Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to Innovent Biologics’ olverembatinib for the treatment of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour (GIST).

Olverembatinib is intended for the treatment of succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumour. Credit: Olga Guryanova on Unsplash.